• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Con­tro­ver­sial Duchenne MD play­er Sol­id Bio takes an­oth­er hit, lay­ing off staffers in a bid to weath­er FDA hold

4 years ago
R&D

Re­gen­eron’s piv­otal tri­al for an ul­tra-rare dis­ease fails the pri­ma­ry — but don't count them out at the FDA

4 years ago
R&D

Sanofi antes up $55M to add pro­tein degra­da­tion tech to the R&D play­book as ex­ecs look to re­vive the pipeline

4 years ago
R&D

Mer­ck­'s Keytru­da wins an­oth­er first — this time for an FDA nod to treat a sub­set of blad­der can­cer pa­tients

4 years ago
Pharma
FDA+

ADC Ther­a­peu­tics clears a big hur­dle to­ward its first BLA as piv­otal PhII de­liv­ers up­beat ORR re­sults

4 years ago
R&D

Scoop: Sanofi qui­et­ly ties up with a low-pro­file, pre­clin­i­cal can­cer biotech — FTC signs off

4 years ago
R&D

Thomas Lynch finds a new home as leader of the Fred Hutch — and he’s stay­ing fo­cused on can­cer break­throughs

4 years ago
People
R&D

Apel­lis soars as Alex­ion ri­val out­shines block­buster stan­dard bear­er Soliris — then fresh doubts scut­tle spike

4 years ago
R&D

A Bay Area biotech spells out the stock pack­age it used to woo a new CEO from Big Phar­ma

4 years ago
R&D

Fresh from a Pfiz­er buy­out, Lu­ca Santarel­li’s crew has cre­at­ed a new com­pa­ny — bank­ing new funds and steer­ing their lead drug to a piv­otal

4 years ago
Financing
Startups

Mer­ck­'s PD-1 star Keytru­da flunks a key sur­vival end­point in SCLC — cue the un­fa­vor­able Tecen­triq com­par­isons

4 years ago
R&D

As ques­tions swirl around lead drug, Fi­bro­Gen (and As­traZeneca) find a new cham­pi­on from Big Phar­ma

4 years ago
People
R&D

Mer­ck dives deep­er in­to KRAS, team­ing up with Tai­ho, As­tex to de­vel­op small mol­e­cule drugs

4 years ago
Deals

FDA of­fers As­traZeneca a short­cut on a land­mark SGLT2 ap­proval while Chi­na green­lights Lokel­ma

4 years ago
Pharma
FDA+

Il­lu­mi­na's $1.2B buy­out dies amid FTC 'mo­nop­o­list' ac­cu­sa­tion

4 years ago
Deals

In­cyte takes a beat­ing as a key PhI­II study flops in their lat­est painful set­back — block­buster hopes crushed

4 years ago
R&D

Biotech bil­lion­aire spends $88M to re­or­ga­nize his long-suf­fer­ing bio­engi­neer­ing busi­ness­es, hands off CEO role

4 years ago
R&D

‘No one ex­pects to get a knight­hood’: As­traZeneca’s Mene Pan­ga­los knight­ed for his lead­ing role in UK life sci­ences

4 years ago
People

Wave spot­lights ‘pos­i­tive’ da­ta on Hunt­ing­ton’s drug, but stock takes a beat­ing as Roche, Io­n­is ri­val stays in front

4 years ago
R&D

An­tibi­otics apoc­a­lypse: Melin­ta files for bank­rupt­cy pro­tec­tion as a plague of woes af­flicts the field

4 years ago
R&D

On a spree, Astel­las bags a next-gen, Park­er-backed CAR-T plat­form with $665M buy­out deal

4 years ago
R&D

Biotech takes a Christ­mas beat­ing af­ter safe­ty fears force re­searchers to halt all hep B stud­ies

4 years ago
R&D

Spec­trum shares crater as first round of piv­otal da­ta for their TKI falls short of pri­ma­ry end­point

4 years ago
R&D

The top 10 most pop­u­lar End­points News pieces of 2019 — go­ing vi­ral is a whole new game in bio­phar­ma now

4 years ago
R&D
First page Previous page 172173174175176177178 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET